Review Article
Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies
Table 2
Clinical data from studies with the main agents in clinical development in differentiated thyroid cancer.
| Author (ref) | Pharmaceutical compound | | Response rate (%) | Stabilizations (%) | Progression-free survival (months) |
|
Gupta-Abramson et al. [16] | Sorafenib | 30 | 23 | 53 | 20 |
Kloss et al. [17] | Sorafenib | 41 | 15 | 56 | 15 |
Ahmed et al. [18] | Sorafenib | 34 | 20 (DTC) | 48 | 12 |
Hoftijzer et al. [19] | Sorafenib | 31 | 24 | 34 | 14 |
Capdevila et al. [20] | Sorafenib | 34 (16 DTC) | 19 (DTC) | 50 (DTC) | 13.5 |
Leboulleux et al. [21] | Vandetanib | 145 | 8.3 versus 5.5 | 48 versus 37 | 11 versus 5.8 |
Cohen et al. [22] | Axitinib | 60 | 30 | 38 | 18 |
Carr et al. [23] | Sunitinib | 33 | 13 (DTC) | 68 (DTC) | 12.8 |
Cohen et al. [24] | Sunitinib | 31 | 13 | 63 | Not reported |
Sherman et al. [25] | Lenvatinib | 56 | 47 (DTC) | 36 (DTC) | Not reported |
Sherman et al. [26] | Motesanib | 93 | 24 | 67 | 10 |
Bible et al. [27] | Pazopanib | 37 | 49 | 46 | 11.8 |
|
|